Overview

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

Status:
Completed
Trial end date:
2017-10-13
Target enrollment:
Participant gender:
Summary
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
Phase:
Phase 3
Details
Lead Sponsor:
Foamix Ltd.
Vyne Therapeutics Inc.
Treatments:
Minocycline